BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/7/2020 2:46:34 PM | Browse: 1101 | Download: 2505
 |
Received |
|
2019-12-08 16:20 |
|
Peer-Review Started |
|
2019-12-08 16:20 |
|
First Decision by Editorial Office Director |
|
2020-01-19 19:10 |
|
Return for Revision |
|
2020-01-19 19:10 |
|
Revised |
|
2020-03-06 08:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-03-18 11:00 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-03-19 01:00 |
|
Articles in Press |
|
2020-03-19 01:00 |
|
Edit the Manuscript by Language Editor |
|
2020-03-27 01:48 |
|
Typeset the Manuscript |
|
2020-04-06 00:56 |
|
Publish the Manuscript Online |
|
2020-04-07 14:46 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Estephany Abou Jokh Casas, Virginia Pubul Núñez, Urbano Anido-Herranz, Maria del Carmen Mallón Araujo, Maria del Carmen Pombo Pasín, Miguel Garrido Pumar, José Manuel Cabezas Agrícola, José Manuel Cameselle-Teijeiro, Ashraf Hilal and Álvaro Ruibal Morell |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Estephany Abou Jokh Casas, MD, Occupational Physician, Department of Nuclear Medicine, Santiago de Compostela´s University Hospital, Avenida Choupana, Santiago de Compostela 15706, A Coruña, Spain. estephanyaboujokh@gmail.com |
| Key Words |
Peptide receptor radionuclide therapy; Gastropancreatic neuroendocrine tumors; Radiological response; Metabolic response; ; |
| Core Tip |
Peptide receptor radionuclide therapy has been used successfully in patients diagnosed with metastatic gastroenteropancreatic somatostatin receptor positive tumors when cytoreductive options are limited. In this study we found that overall survival was inversely proportional to toxicity to previous treatments and directly proportional to matching lesion findings between octreoscan and computed tomography pre-peptide receptor radionuclide therapy, tumor grade, bone metastasis and primary tumor and metastasis surgery. Also, that pseudo-progression in the middle of the treatment was a common finding that should be taken into consideration by clinicians in daily practice. |
| Publish Date |
2020-04-07 14:46 |
| Citation |
Abou Jokh Casas E, Pubul V, Anido-Herranz U, Mallón M, Pombo M, Garrido M, Cabezas JM, Cameselle JM, Hilal A, Ruibal Á. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524
|
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i13/1513.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i13.1513 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
